Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
- PMID: 19824849
- DOI: 10.1086/644494
Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Comment on
-
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114. Clin Infect Dis. 2009. PMID: 19438397 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
